FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TATEMENT	OF CHA	ANGES IN	<b>BENEFICIAL</b>	<b>OWNERSHIP</b>

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section 30(h) of the Investment Company Act of 1940					
Name and Address of Reporting Person*			2. Issuer Name <b>and</b> Ticker or Trading Symbol  Blueprint Medicines Corp [ BPMC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Albers Jeffrey W.			Bracking Gork [ Bring ]	X	Director	10% Owner		
(Last) (First) (Middle)		• •	3. Date of Earliest Transaction (Month/Day/Year) 03/02/2018	X	Officer (give title below)  CEO and Pre	Other (specify below)		
C/O BLUEPRINT MEDICINES CORPORATION			05/02/2015		CLO and Th	Sident		
45 SIDNEY STREET								
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	vidual or Joint/Group Filir	ng (Check Applicable		
CAMBRIDGE	MA	02139		X	Form filed by One Rep	porting Person		
					Form filed by More that Person	an One Reporting		
(City)	(State)	(Zip)			Person			
		Table I - Non-Deriv	ative Securities Acquired, Disposed of, or Benefi	cially	Owned			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 4. Securities Acquired (A Disposed Of (D) (Instr. 3,			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(IIISU. 4)	
Common Stock	03/02/2018		M <sup>(1)</sup>		20,000	A	\$1.87	20,000	D		
Common Stock	03/02/2018		<b>S</b> <sup>(2)</sup>		6,022	D	<b>\$94.79</b> <sup>(3)</sup>	13,978	D		
Common Stock	03/02/2018		S <sup>(2)</sup>		3,794	D	\$93.89(4)	10,184	D		
Common Stock	03/02/2018		S <sup>(2)</sup>		1,900	D	\$92.76(5)	8,284	D		
Common Stock	03/02/2018		S <sup>(2)</sup>		4,100	D	\$91.66(6)	4,184	D		
Common Stock	03/02/2018		<b>S</b> <sup>(2)</sup>		600	D	\$90.52(7)	3,584	D		
Common Stock	03/02/2018		S <sup>(2)</sup>		2,284	D	\$89.07(8)	1,300	D		
Common Stock	03/02/2018		<b>S</b> <sup>(2)</sup>		1,300	D	\$88.17(9)	0	D		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to	\$1.87	03/02/2018		M			20,000	(10)	07/30/2024	Common Stock	20,000	\$0	975,034	D	

## **Explanation of Responses:**

- 1. The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- 2. The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016, as amended December 20, 2017, pursuant to Rule 10b5-1 under the Exchange Act.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$94.31 to \$95.30 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (9) to this Form 4.
- 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.37 to \$94.30 per share.
- 5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$92.44 to \$93.25 per share.
- 6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$91.32 to \$92.24 per share.
- 7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$90.33 to \$90.74 per share.
- 8. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$88.63 to \$89.50 per share.
- 9. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$87.79 to \$88.48 per share.
- 10. This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018.

/s/ Christopher Frankenfield, Attorney-in-Fact

03/06/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.